Work for Clementia Pharmaceuticals Inc.?

Claim Your Profile

Clementia Pharmaceuticals Inc. Logo Image

Clementia Pharmaceuticals Inc.

Clementia Pharmaceuticals Inc. Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.co.uk

2018 Annual Report

Clementia Pharmaceuticals Inc.

Annual
Report

Clementia Pharmaceuticals Inc. has reached its limit for free report views.

Upgrade your company profile to unlock all of your annual report content on AnnualReports.co.uk

Archived Annual Reports

  • Clementia Pharmaceuticals Inc.

About Clementia Pharmaceuticals Inc.

Based in Montreal, Quebec

Clementia (CMTA: Nasdaq) is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RARγ agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in adults and children with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RARγ therapy.

Ticker:
CMTA
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
--None-- (See More --None-- Companies)
Sector:
--None-- (See More --None-- Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol